Ozoralizumab (trade name Nanozora) is a trivalent anti-tumour necrosis factor alpha (TNFα) nanobody designed for the treatment of inflammatory diseases.[1]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Clinical data | |
| Trade names | Nanozora |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C1682H2608N472O538S12 |
| Molar mass | 38434.85 g·mol−1 |
  (what is this?) (verify) | |
Ozoralizumab was developed by Pfizer Inc, and now belongs to Ablynx NV. Ablynx has licensed the rights to the antibody in China to Eddingpharm. In 2022, ozoralizumab was approved in Japan for the treatment of rheumatoid arthritis.[2]